Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2023 / Oct / No Further PRoblems
Retina

No Further PRoblems

Study shows effect of prophylactic ranibizumab (PR) on drusen volume, macular layer thicknesses, and progression of GA

By Oscelle Boye 10/30/2023 2 min read

Share

Credit: Image sourced from Rawpixel.com

Like trying to extinguish a gasoline fire with water, sometimes our best efforts to make things better end up making things far worse. Because of its prevention of proliferation, vascular permeability and neovascularization, the humanized, anti-vascular endothelial growth factor A (VEGF-A) prophylactic, ranibizumab (PR), is used as a treatment for age-related macular degeneration (AMD), specifically the more severe neovascular or exudative AMD (nAMD). Although its mechanism of action has been demonstrated, the question still stands: what effect does it have on the anatomical structures of the retina? Is it only doing what we expect, or is it causing unforeseen problems?

“Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration” is a new study published in ARVO’s Translational Vision Science & Technology and conducted by a research group from an American multi-institutional team (1). In this study, researchers compared the eyes of patients with intermediate age-related macular degeneration (AMD) that had been injected with PR every three months, with those given a sham injection. Over the course of 24 months, the researchers determined the effect of PR on drusen volume, macular layer thicknesses, and the progression of geographic atrophy (GA) area over 24 months in the PREVENT trial.

The results showed that PR given every three months did not appear to worsen the progressive retinal degenerative process as there were no statistical differences between the groups in anatomic parameters including drusen area and volume, macular thinning, or geographic atrophy progression in the eyes of patients with intermediate AMD. As the researchers concluded, “Our results have shown that this progressive retinal degenerative process was not worsened by quarterly dosing of ranibizumab in these eyes at risk for vision loss. Future studies with a more robust sample size and longer follow-up time may provide confirmation of the outcomes shown in this study and may elucidate additional relevant information on this topic.”

References

  1. CK Chan et al., “Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration,” Transl Vis Sci Technol, 12, 1 (2023). PMID: 3765644

About the Author(s)

Oscelle Boye

I have always been fascinated by stories. During my biomedical sciences degree, though I enjoyed wet lab sessions, I was truly in my element when sitting down to write up my results and find the stories within the data. Working at Texere gives me the opportunity to delve into a plethora of interesting stories, sharing them with a wide audience as I go.

More Articles by Oscelle Boye

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: